A recentmeta-analysis focusing on cardiovascular and kidney outcomes in diabetics foundthat use of GLP-1R agonists improved a number of cardiovascular biomarkers andreduce all-cause major adverse cardiovascular events, a composite outcomeincluding nonfatal myocardial infarction, stroke, and cardiovasculardeath.172Additionally, in the more recent SELECT173 and STEP-HFpEF174 clinical trials, the GLP-1R agonist semaglutideimproved cardiovascular outcomes in patients with obesity in the absence ofdiabetes. Here, GLP1R is linked to obesity disorder.